| Abstract | We describe the use of pamidronate to control marked hypercalcemia in an extremely premature infant with neonatal hyperparathyroidism that resulted from an inactivating mutation (R220W) of the calcium-sensing receptor. Despite improvement in bone mineralization and subsequent parathyroidectomy with normalization of the serum calcium level, the combination of chronic lung disease, osteomalacia, and poor thoracic cage growth ultimately proved fatal. Pamidronate therapy seems to be safe in the short-term and effective in helping control hypercalcemia even in the very premature infant, allowing for planned surgical intervention when it becomes feasible. |
| Authors | Lisa Fox, Joel Sadowsky, Kevin P Pringle, Alexa Kidd, Jean Murdoch, David E C Cole, Esko Wiltshire
(Affiliation: Department of Paediatrics and Child Health, Wellington Hospital, Capital and Coast District Health Board, Wellington, New Zealand. lisa.fox at rwh.org.au)
|
| Journal | Pediatrics
(Pediatrics)
Vol. 120
Issue 5
Pg. e1350-4
(Nov 2007)
ISSN: 1098-4275 United States |
| PMID | 17974727
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Diphosphonates
- pamidronate
|
| Topics |
- Diphosphonates
(therapeutic use)
- Fatal Outcome
- Female
- Humans
- Hyperparathyroidism
(drug therapy, radiography)
- Infant
- Infant, Newborn
- Infant, Premature
- Infant, Very Low Birth Weight
|
